Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis


1 Department of Physiology, Applied Physiology Research Center, Isfahan University of Medical Sciences, Hezar Jerib Avenue, Isfahan, Iran

2 Department of Neurology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Decreased concentration of tissue factor pathway inhibitor (TFPI) is a risk factor for development of deep venous thrombosis and coronary heart disease, but there is no evidence for the relationship between TFPI and cerebral venous and sinus thrombosis (CVST). The aim of this study was to determine the level of TFPI in healthy population and in patients with CVST.
Materials and Methods: We determined the plasma level of TFPI in 20 patients with CVST (cases) and 31 healthy volunteer subjects (as control group) by enzyme linked immunoassay method. We also examined the association between TFPI and the risk of CVST. Continuous variables were compared between groups using Student's t test, and odds ratio was calculated by multiple logistic regression analysis.
Results: The mean TFPI was significantly lower in the CVST group compared with the control group (8.60 ± 4.05 ng/mL; 14.6 ± 8.6 ng/mL; P = 0. 005), respectively. The odds ratio for CVST associated with low (<25 th percentile) levels of TFPI was 5.429 (95% CI, 1.487-19.82, P = 0.012).
Conclusion: Our investigation demonstrates that reduced TFPI may be one of the risk factors of CVST and associated with increasing the risk of developing CVST.


Janghorbani M, Zare M, Saadatnia M, Mousavi SA, Mojarrad M, Asgari E. Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: Frequency and seasonal variation. Acta Neurol Scand 2008;117:117-21.  Back to cited text no. 1
Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;352:1791-8.  Back to cited text no. 2
Shahsavarzadeh T, Javanmard SH, Saadatnia M. Impact of factor VIII and von Willebrand factor plasma levels on cerebral venous and sinus thrombosis: Are they independent risk factors? Eur Neurol 2011;66:243-6.  Back to cited text no. 3
Saadatnia M, Fatehi F, Basiri K, Mousavi SA, Mehr GK. Cerebral venous sinus thrombosis risk factors. Int J Stroke 2009;4:111-23.  Back to cited text no. 4
Whitlatch NL, Ortel TL. Thrombophilias: When should we test and how does it help? Semin Respir Crit Care Med 2008;29:25-39.  Back to cited text no. 5
Masuhr F, Mehraein S, Einhäupl K. Cerebral venous and sinus thrombosis. J Neurol 2004;251:11-23.  Back to cited text no. 6
Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: Structure, biology and involvement in disease. J Pathol 2006;208:327-39.  Back to cited text no. 7
Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-72.  Back to cited text no. 8
Yamamuro M, Wada H, Kumeda K, Inoue A, Tsuji I, Nakasaki T, et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1998;9:491-7.  Back to cited text no. 9
Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22:539-48.  Back to cited text no. 10
Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001;113:537-43.  Back to cited text no. 11
Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005;94:787-90.  Back to cited text no. 12
Dahm A, Van Hylckama Vlieq A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-92.  Back to cited text no. 13
Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, et al. Endothelial cell markers and the risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-8.   Back to cited text no. 14
Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: A randomized controlled study. J Thromb Haemost 2003;1:1208-14.   Back to cited text no. 15
Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (Lond) 2001;101:93-9.  Back to cited text no. 16
Koh KK, Ahn JY, Kim DS, Han SH, Shin MS, Ryu WS, et al. Effect of hormone replacement therapy on tissue factor activity, c-reactive protein, and the tissue factor pathway inhibitor. Am J Cardiol 2003;91:371-3.  Back to cited text no. 17
Shirk RA, Zhang Z, Winneker RC. Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol 2005;94:361-8.  Back to cited text no. 18
Hinnell C, Nadeau J, Lam V, Hill MD, Coutts SB. Sex differences in adult cerebral venous sinus thrombosis: A 10-year experience. Can J Neurol Sci 2012;39:74-7.  Back to cited text no. 19
Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009;29:2015-20.  Back to cited text no. 20
Dahlback B. The tale of protein S and C4b-binding protein, a story of affection. Thromb Haemost 2007;98:90-6.  Back to cited text no. 21
Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:27852-8.  Back to cited text no. 22
Hackeng TM, Seré KM, Tans G, Rosing J. Protein S. stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006;103:3106-11.  Back to cited text no. 23
Dahm AE, Sandset PM, Rosendaal FR. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 2008;6:393-5.  Back to cited text no. 24
Sidelmann JJ, Bladbjerg EM, Gram J, Münster AM, Jespersen J. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis. Blood Coagul Fibrinolysis 2008;19:405-9.  Back to cited text no. 25